Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NeuroPace, Inc.
  6. Summary
    NPCE   US6412881053

NEUROPACE, INC.

(NPCE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
19.15(c) 18.1(c) 17.54(c) 17.75(c) 17.42 Last
67 072 211 938 100 425 36 610 126 682 Volume
-6.40% -5.48% -3.09% +1.20% -1.86% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 47,2 M - -
Net income 2021 -32,9 M - -
Net Debt 2021 1,09 M - -
P/E ratio 2021 -10,7x
Yield 2021 -
Sales 2022 57,8 M - -
Net income 2022 -27,2 M - -
Net Debt 2022 7,69 M - -
P/E ratio 2022 -15,3x
Yield 2022 -
Capitalization 431 M 431 M -
EV / Sales 2021 9,16x
EV / Sales 2022 7,59x
Nbr of Employees 159
Free-Float 7,65%
More Financials
Company
NeuroPace, Inc. is a commercial-stage medical device company. The Company is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a... 
More about the company
All news about NEUROPACE, INC.
09/09NEUROPACE INC : Regulation FD Disclosure (form 8-K)
AQ
08/23NEUROPACE : to Participate in Upcoming Conferences
AQ
08/18NEUROPACE : Baird Starts NeuroPace at Outperform With $26 Price Target
MT
08/12NEUROPACE : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
08/12NEUROPACE : Q2 Loss Narrows Sharply As Revenue Improves
MT
08/12NEUROPACE : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
08/12NEUROPACE INC : Results of Operations and Financial Condition, Financial Stateme..
AQ
08/12NEUROPACE : Earnings Flash (NPCE) NEUROPACE Reports Q2 Revenue $12.6M, vs. Stree..
MT
08/12NEUROPACE : Reports Second Quarter 2021 Financial Results
AQ
08/12NeuroPace, Inc. Reiterates Financial Guidance for the Full Year of 2021
CI
08/12NeuroPace, Inc. Reports Unaudited Financial Results for the Second Quarter an..
CI
08/04NEUROPACE : Launches nSight Platform and Partnership with Seizure Tracker™..
BU
08/04NeuroPace, Inc. Announces the Broad Launch of Its nSight Platform
CI
07/22NEUROPACE : To Report Second Quarter 2021 Financial Results on August 12, 2021
AQ
06/30NEUROPACE : Secures $9.3 Million NIH Grant to Evaluate Neuromodulation Technolog..
MT
More news
News in other languages on NEUROPACE, INC.

- No features available -

More news
Analyst Recommendations on NEUROPACE, INC.
More recommendations
Chart NEUROPACE, INC.
Duration : Period :
NeuroPace, Inc. Technical Analysis Chart | NPCE | US6412881053 | MarketScreener
Technical analysis trends NEUROPACE, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 17,75 $
Average target price 27,40 $
Spread / Average Target 54,4%
EPS Revisions
Managers and Directors
Michael Favet President, Chief Executive Officer & Director
Rebecca L. Kuhn CFO, Vice President-Finance & Administration
Frank M. Fischer Chairman
Martha J. Morrell Chief Medical Officer
Cairn Seale Vice President-Clinical & Research
Sector and Competitors
1st jan.Capi. (M$)
NEUROPACE, INC.0.00%431
DANAHER CORPORATION46.42%231 303
THERMO FISHER SCIENTIFIC20.86%220 488
INTUITIVE SURGICAL, INC.26.39%123 038
SIEMENS HEALTHINEERS AG37.68%76 323
EDWARDS LIFESCIENCES CORPORATION32.65%75 229